Several pharmaceutical companies are placing big bets on exosomes and other extracellular vesicles as a means to deliver nucleic acid therapeutics. A spate of deals involving big pharma hints that the industry is embracing exosomes as a means of delivering nucleic acid therapies to hard-to-reach tissues.
Zipkin M. (2020) Big pharma buys into exosomes for drug delivery. Nat Biotechnol 38(11):1226-1228. [abstract]